Summary of InMode Conference Call Company Overview - **Company**: InMode - **Industry**: Medical Devices, specifically in aesthetic treatments Key Points Current Operational Challenges - InMode is currently operating at approximately **60% manufacturing capacity** due to regional instability and threats from neighboring countries [5][6] - The company faces significant **logistical challenges** with shipping, as major carriers like DHL and FedEx are not operating flights to Israel, leading to increased shipping costs [6][7] - Employee attendance is affected by school closures, impacting workforce availability [6] Inventory Management - InMode has built a **safety inventory** of finished goods and components over the past two years, which is currently being utilized to meet market demands despite shipping challenges [11] - The company has shipped products to subsidiaries globally to fill gaps caused by local disruptions [11] Share Buyback Program - InMode has executed a **share buyback program**, purchasing shares worth **$508 million** to date, with an additional **$85 million to $90 million** approved for buyback, totaling around **$600 million** over the last 3.5 years [14][15] - The company aims to maintain liquidity for potential M&A opportunities, targeting acquisitions in the range of **$500 million to $1 billion** [17] Market Trends and Customer Insights - There is a **stabilization** in patient activity and treatment usage, with no significant growth or decline observed [19] - High interest rates on leasing (14%-15%) are affecting customer purchasing decisions, particularly in the U.S. market [20] - The company anticipates potential growth in 2027, contingent on stabilization in 2026 and new product launches [22][33] Product and Technology Development - InMode is focusing on expanding its portfolio to include **non-invasive technologies**, which now contribute nearly **20%** to its revenue [34] - The company is developing new laser technologies to complement its existing RF energy products, aiming for a competitive edge in the market [36][39] - A dedicated team for the **dry eye treatment** platform has been established, with plans to submit for FDA approval for a new RF-based study [41][42] Geographic and Structural Changes - InMode has restructured its North American operations to unify management, aiming for improved efficiency and sales performance [29][30] - The company is also exploring growth opportunities in Asia, particularly in China and Korea, where it currently has limited market presence [46][47] Financial Outlook - Gross margins are impacted by a shift towards more laser-based devices, which traditionally have lower margins, and by tariffs affecting U.S. operations [49][50] - Despite current challenges, there is optimism about the recovery of demand for aesthetic procedures, which is expected to improve margins in the future [51] Additional Insights - The company is cautious about future guidance due to macroeconomic uncertainties and ongoing regional instability [22][50] - InMode's management is actively monitoring the effectiveness of recent organizational changes and is prepared to make further adjustments as necessary [30][32]

Core Insights - West Pharmaceutical Services, Inc. (WST) reported adjusted fourth-quarter 2025 earnings per share (EPS) of $2.04, a 12.1% increase year over year, exceeding the Zacks Consensus Estimate by 11.5% [1] - The company achieved revenues of $805 million in the fourth quarter, reflecting a 7.5% year-over-year growth, surpassing the Zacks Consensus Estimate by 1.4% [2] - Full-year 2025 revenues reached $3.07 billion, marking a 6.3% increase from 2024, with organic revenues up 4.3% year over year [3] Financial Performance - Adjusted EPS for the full year was $7.29, an 8% increase from 2024 [1] - GAAP EPS for the fourth quarter was $1.82, a 2.2% improvement from the previous year [1] - Gross profit for the quarter increased by 11.1% to $303.9 million, with a gross margin expansion of 130 basis points to 37.8% [10] Segment Performance - Proprietary Products segment reported revenues of $661.8 million, up 7.8% year over year, with high-value products accounting for 48% of net sales [7][8] - Contract-Manufactured Products segment revenues totaled $143.2 million, reflecting a 6.2% year-over-year increase [9] Guidance and Outlook - For Q1 2026, WST expects sales between $770 million and $790 million, with EPS projected in the range of $1.65-$1.70 [14] - Full-year 2026 revenues are anticipated to be between $3.21 billion and $3.27 billion, with organic net sales expected to grow 5-7% [15] - Adjusted EPS for 2026 is projected to be in the range of $7.85-$8.20 [16] Strategic Insights - The company attributes its strong performance to consistent execution of its growth strategy, particularly in the high-value product segment [18] - Management expects the momentum to continue into 2026, focusing on operational discipline and growth sustainability [18] - The guidance reflects steady demand fundamentals and favorable currency tailwinds [19]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $103.9 million, up from $97.9 million in Q4 2024, while full-year revenue for 2025 totaled $370.5 million, a 6% decrease compared to 2024 [8][9] - Gross margins for Q4 2025 were 78% on a GAAP basis, down from 79% in Q4 2024, while non-GAAP gross margins were 79% for both Q4 and full year 2025 [9][11] - GAAP diluted earnings per share for Q4 2025 were $0.42, compared to $1.14 in Q4 2024, and $1.43 for the full year 2025, down from $2.25 in 2024 [11][12] Business Line Data and Key Metrics Changes - Revenue from consumables and services increased slightly compared to last year, indicating early signs of stabilization in patient activity [4] - Minimally invasive technology platforms accounted for 76% of total revenues in Q4 2025, while consumables and services represented 22% of revenue, up from 20% in 2024 [9][10] Market Data and Key Metrics Changes - Sales outside the U.S. totaled $48.5 million in Q4 2025, representing 47% of total sales and a 38% increase compared to Q4 2024, driven primarily by Europe [9] - For the full year 2025, sales outside the U.S. accounted for $171.8 million, or 46% of total sales, representing a 15% increase compared to 2024 [9] Company Strategy and Development Direction - The company views 2026 as a stabilization year following a prolonged period of industry softness, with plans to continue innovating and introducing new platforms [4][6] - A specialized sales team has been established for the Envision platform, aimed at increasing penetration and improving sales productivity [5] - The company plans to launch two new platforms in 2026, including a Korean-made Pico laser device and a device combining new Morpheus technology with Erbium YAG laser [6] Management's Comments on Operating Environment and Future Outlook - Management noted that the industry has not yet fully recovered from the global economic slowdown, with demand in North America remaining below historical levels, but there are early signs of stabilization [7] - The CEO mentioned that interest rates starting to come down could positively impact leasing packages for capital equipment purchases [17] Other Important Information - The company returned $127.4 million to shareholders through a disciplined share repurchase program [13] - The board of directors is exploring strategic alternatives to improve company value, having engaged Bank of America for assistance [20] Q&A Session Summary Question: What signs suggest improving trends in the market? - Management noted a slight increase in procedures and sales in consumables, along with declining interest rates as positive indicators [17] Question: Can you provide updates on strategic alternatives? - The board is considering several strategic alternatives and has engaged Bank of America for assistance, with management not directly involved in the process [20] Question: What are the expectations for gross margins and EBIT margins? - Management indicated that new product launches, particularly lasers, may impact gross margins, and guidance is conservative based on past experiences [27][28] Question: How is the ApexRF platform performing? - The ApexRF platform is being sold alongside other products without a specialized sales team, and management is awaiting FDA indications before pushing it further [72] Question: What is the contribution of new product launches for 2026? - Two new products are expected to be launched in 2026, with significant marketing efforts planned, although specific financial contributions are not yet provided [41]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $103.9 million, up from $97.9 million in Q4 2024, while full-year revenue for 2025 totaled $370.5 million, a 6% decrease compared to 2024 [7][8] - Gross margins in Q4 2025 were 78% on a GAAP basis, down from 79% in Q4 2024, while Non-GAAP gross margins remained at 79% for both Q4 and full year 2025 [8][10] - GAAP diluted earnings per share for Q4 were $0.42, compared to $1.14 in Q4 2024, and $1.43 for the full year 2025, down from $2.25 in 2024 [10][11] Business Line Data and Key Metrics Changes - Revenue from consumables and services increased slightly compared to last year, indicating early signs of stabilization in patient activity [4] - Minimally invasive technology platforms accounted for 76% of total revenues in Q4 2025, while consumables and services represented 22% of revenue, up from 20% in 2024 [8] Market Data and Key Metrics Changes - Sales outside the U.S. totaled $48.5 million in Q4 2025, representing 47% of total sales and a 38% increase compared to Q4 2024, driven primarily by Europe [8] - For the full year 2025, international sales accounted for $171.8 million, or 46% of total sales, reflecting a 15% increase compared to 2024 [8] Company Strategy and Development Direction - The company views 2026 as a stabilization year following a prolonged period of industry softness, with a focus on disciplined execution of its product roadmap and maintaining leadership in the aesthetic industry [4][6] - Product innovation remains a key pillar, with plans to launch two new platforms in 2026, including a Korean-made Pico laser device and a device combining new Morpheus technology with Erbium YAG laser [5][6] Management's Comments on Operating Environment and Future Outlook - Management noted that early signs of stabilization in the U.S. market and gradual improvement in Europe could support future performance [6] - The company is encouraged by a slight increase in procedures and sales in consumables, indicating potential recovery in the aesthetic space [16] Other Important Information - The company has returned $127.4 million to shareholders through a disciplined share repurchase program [11] - The board is exploring strategic alternatives to enhance company value, including hiring Bank of America for assistance [19] Q&A Session Summary Question: What signs suggest improving trends in the market? - Management noted declining interest rates and a slight increase in procedures and consumables sales as early signs of improvement [16] Question: Can you provide updates on strategic alternatives? - The board is considering several strategic alternatives to improve company value, with no direct involvement from management in the process [19] Question: What are the expectations for gross margins and EBIT margins? - Management indicated that new product launches, particularly lasers, may impact gross margins, which are expected to be in the neighborhood of 75% [29] Question: How is the ApexRF platform performing? - The ApexRF platform is being sold alongside other products without a specialized sales team, and management is awaiting FDA indications before pushing it further [73] Question: What is the outlook for international revenue? - Management expressed optimism about increasing direct sales in new subsidiaries, but could not definitively state if international revenue would surpass North America [58]

Financial Data and Key Metrics Changes - InMode generated revenues of $93.2 million in Q3 2025, down from $130.2 million in Q3 2024, which included $31.9 million in pre-order sales [6][7] - Consumables and service revenues were $19.9 million, up 26% year-over-year, driven primarily by markets outside the U.S. [6][7] - GAAP gross margins were 78%, down from 82% in Q3 2024, attributed to the impact of tariffs [7][8] - GAAP net income was $21.8 million, down from $50.9 million in Q3 2024, with diluted earnings per share at $0.34, down from $0.65 [9][10] Business Line Data and Key Metrics Changes - Minimally invasive platforms accounted for 75% of total revenues this quarter [7] - Sales outside the U.S. increased slightly to $40 million, or 43% of overall sales, a 10% increase year-over-year [7] - Sales and marketing expenses decreased to $44.9 million from $51.9 million in the same period last year [8] Market Data and Key Metrics Changes - The U.S. was the largest geographical revenue contributor, reaching $53.2 million [7] - The company currently has 284 direct sales reps and distributors covering more than 73 countries [8] Company Strategy and Development Direction - The company is focused on expanding its presence in high-growth markets, recently opening a new subsidiary in Argentina [3][4] - A new leadership addition, Michael Denison, was appointed as President of North America to streamline operations [5][28] - The company aims to launch new products in the aesthetic segment in early 2026, including new lasers [26] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in the marketplace but expressed confidence in the company's competitive advantages and strong financial position [5] - The company plans to remain conservative in its guidance for 2026 due to uncertainties in the market [14][16] Other Important Information - The company expects to begin generating initial revenue from its new subsidiary in Argentina by the end of 2025 [4] - Non-GAAP gross margins are expected to remain between 78%-80% for 2025 [10] Q&A Session Summary Question: Guidance for Q4 and 2026 sales growth - Management indicated it is too early to discuss guidance for 2026 and prefers to see how Q4 plays out first [14] Question: Capital equipment environment and interest rates - Management noted that while interest rates have come down, it has not yet significantly impacted capital equipment financing [16][17] Question: Updates on ophthalmology initiative - The company is separating sales teams for the Envision initiative and has made progress with the American Optometrist Association [20][21] Question: New product pipeline in aesthetics - New lasers complementary to the aesthetic portfolio are expected to be launched in early 2026 [26] Question: Rationale for appointing Michael Denison - Denison was chosen for his extensive experience and knowledge of the market, aiming to unify North American operations under one management [28][29] Question: Urology business expectations - The company is launching urology products and will assess their performance by the end of the year [30] Question: Strength in OUS business and future trends - The company is currently selling in 88 to 90 countries and does not plan to add more countries in 2025 [33][34] Question: Non-invasive growth and consumables - The company sold about 230,000 disposable handpieces in Q3 2025, indicating a sequential increase [41]

Financial Data and Key Metrics Changes - Total revenue for Q3 was $1,024 million, representing a slight growth of 0.4% year-over-year, exceeding guidance by approximately $14 million [8][17] - Non-GAAP earnings per share reached $1.08, a 1.9% increase compared to the previous year, and above the high end of guidance [8][32] - Non-GAAP operating margin was maintained just above 30%, reflecting effective expense control [8][32] Business Line Data and Key Metrics Changes - Diagnostics revenue was $448.9 million, growing 0.9% overall and 2.9% organically, excluding COVID-related sales [18] - Breast Health revenue was $365.2 million, declining 5.8% or 10.8% organically, but showed sequential growth compared to Q2 [26] - Surgical revenue increased by 6.3% to $178.4 million, with international growth leading at 24.8% [27] - Skeletal revenue grew significantly by 62.1% to $31.3 million, driven by resumed shipping of DEXA models [29] Market Data and Key Metrics Changes - The diagnostics business faced challenges due to geopolitical issues, particularly in China and funding cuts in Africa, impacting growth [18][20] - The Breast Health business is expected to rebound, with improved sales execution and new product launches anticipated to drive future growth [9][26] Company Strategy and Development Direction - The company aims for mid-single-digit organic revenue growth in the upcoming fiscal year, supported by a strengthened Breast Health business and ongoing product innovations [9][36] - Focus on enhancing the Breast Health portfolio through new product launches and improved sales strategies [10][12] - Continued investment in international markets is expected to contribute positively to overall growth [101] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about returning to solid growth, citing progress in overcoming recent challenges [6][9] - The company anticipates a strong Q4, with expectations for revenue growth driven by improved sales execution and product offerings [36][38] - Management acknowledged headwinds from geopolitical factors affecting diagnostics but remains confident in the underlying growth drivers [18][20] Other Important Information - The company has made significant progress in mitigating tariff impacts, reducing expected tariff expenses to $10-12 million per quarter [30][31] - The discontinuation of the Fluoriscan product is expected to have a minimal impact on overall revenue [46][77] Q&A Session Summary Question: Outlook for fiscal 2026 and potential headwinds - Management expects mid-single-digit growth for fiscal 2026, with headwinds from the discontinuation of Fluoriscan and challenges in China and HIV funding impacting growth [46][47] Question: Capital allocation and M&A considerations - The company has focused on share buybacks and remains open to M&A opportunities but has no significant deals in the pipeline currently [51][110] Question: Visibility into Breast Health business for Q4 - Management is confident in the Breast Health business's recovery, supported by improved sales force execution and new product launches [60][62] Question: Impact of tariffs and mitigation strategies - The company has successfully mitigated about half of the anticipated tariff impacts through operational efficiencies [114][116] Question: Diagnostic growth expectations for fiscal 2026 - Diagnostics growth is expected to be in the mid-single-digit range, influenced by headwinds from China and HIV funding [122][124]

Summary of Hologic Conference Call Company Overview - **Company**: Hologic - **Industry**: Life Sciences, specifically focusing on women's health diagnostics and surgical solutions Key Points and Arguments 1. Business Segments Performance - **Diagnostics Division**: Largest segment, includes cytology and molecular diagnostics - Cytology has been a low single-digit growth area, facing headwinds in China due to local competition and anti-American sentiment [5][6] - Molecular diagnostics, particularly the BVCV vaginitis assay, has shown steady high single-digit growth [6] - HIV business in Africa faced a setback with the cessation of USAID funding, previously generating $50 million annually [6] - **Breast Health Business**: - Dominates the market with 70-80% share but has struggled recently due to lower gantry placements [9][11] - New leadership and a bifurcated sales force are expected to improve performance [11][12] - Recent acquisition of Endomagnetics is anticipated to enhance growth [7][25] - **Surgical Business**: Focused on treating abnormal uterine bleeding and fibroids, with a strong market position [8][50] - Recent acquisition of Gynasonics is expected to broaden the fibroid treatment portfolio [50][53] 2. Market Dynamics and Challenges - **China Market**: Revenue guidance reduced by $20 million to $50 million due to tariffs and local competition [30] - Current revenue from China is only about 2% of total, with a derisked annual business estimate of $30 million [30] - **Tariff Implications**: Estimated impact of $20 to $25 million per quarter, primarily from products sourced from Costa Rica [29] - Ongoing efforts to mitigate tariff impacts are in place [29] 3. Growth Outlook - **Fourth Quarter Guidance**: Expected growth of 5% after a decline of 2.5% to 3.5% in Q3, driven by recovery in breast health and contributions from Endomagnetics [32] - **Long-term Growth Projections**: - Diagnostics expected to lead growth, particularly molecular diagnostics [57] - Breast health anticipated to grow at the lower end of mid-single digits, while surgical is expected to grow at the higher end [57] 4. Innovations and Future Products - **Genius Digital Cytology**: Aims to enhance cervical cancer screening through digitization and AI, expected to drive growth in cytology [35] - **Envision Launch**: Targeted for 2026, expected to offer premium features and improved patient experience [17][19] 5. Financial Health and Capital Allocation - **Cash Position**: Company holds $1.6 billion in cash, with a focus on M&A and share repurchase to manage dilution [62] - **Operating Margins**: Expected to remain in the low 30% range, with ongoing efforts to optimize costs and mitigate tariff impacts [58] 6. Employee Engagement and Corporate Culture - **Workforce Morale**: High engagement levels reported, with a focus on the mission of championing women's health [70][71] Additional Important Insights - **Competitive Landscape**: Local competition in China is not new, but recent geopolitical tensions have intensified challenges [68][69] - **Self-Collection Trends**: The trend towards self-collection for screenings is acknowledged, but the company emphasizes the importance of traditional methods for effective cancer detection [64][66] This summary encapsulates the key insights from Hologic's conference call, highlighting the company's performance, market challenges, growth strategies, and future outlook.

Summary of InMode Conference Call Company Overview - InMode is a medical technology company based in Israel, established approximately 16 years ago, specializing in minimally invasive aesthetic procedures using radio frequency technology [4][5] - The company has grown from $22 million in annual revenue to nearly $500 million in 2023 [4] Recent Performance and Market Conditions - InMode has faced challenges over the past two years due to a slow global economy, particularly in the US and Europe [5][8] - The stock price has fluctuated significantly, reaching a high of around $80 before dropping to approximately $14 [9] - The company expects flat revenue growth for the year, with Q1 performance being softer than anticipated [11][12] Revenue Guidance and Profitability - The revenue mix shifted to a 50/50 split between US and international sales, contrary to previous expectations of 62-65% from the US [12] - Europe had a record quarter in Q1, while the US faced unexpected headwinds [12][17] - Adjustments were made to profitability estimates due to the revenue mix and new tariffs affecting products manufactured in Israel [13][14] Product Development and Pipeline - InMode is expanding its product offerings into women's health and ophthalmology, with two new platforms launched [21][23] - The Empower system for pelvic floor restoration generated $40 million in its first year but saw a 20% decline in 2024 [25][27] - Ongoing studies for overactive bladder treatments are expected to conclude by 2026, with promising preliminary results [31][32] - The company has 15 R&D projects in the pipeline, aiming to release two new products annually [28][29] Sales Force and Capital Allocation - The North American sales force has been restructured into three territories to improve management and efficiency [34][36] - InMode has repurchased $508 million worth of shares over the past two years, buying back 30% of outstanding shares [39] - Future capital allocation strategies include potential share buybacks, internal investments, or acquisitions, with a focus on maintaining flexibility [40][41] Competitive Landscape and Future Outlook - The company is positioned to benefit from reduced competition in the aesthetic market as other companies struggle [48] - InMode's management believes that they will emerge stronger from the current economic slowdown, leveraging their resources and technology [46][47] - The outlook for growth in 2026 remains uncertain, dependent on broader economic conditions [50]

Financial Data and Key Metrics Changes - InMode generated total revenue of $77.9 million in Q1 2025, a decrease of 3% compared to Q1 2024 [8] - GAAP gross margin was 78% in Q1 2025, down from 80% in Q1 2024 [8] - Non-GAAP diluted earnings per share were $0.31, compared to $0.32 in Q1 2024 [12] Business Line Data and Key Metrics Changes - Minimally invasive platforms accounted for 87% of total revenues in Q1 2025 [9] - Sales and marketing expenses decreased slightly to $39.7 million in Q1 2025 from $39.8 million in the same period last year [11] Market Data and Key Metrics Changes - International sales accounted for $38 million or 49% of total sales, a 1% increase compared to Q1 2024 [10] - Europe was the largest revenue contributor from outside the U.S., achieving record sales [10] Company Strategy and Development Direction - The company plans to unveil a new platform for the wellness market later in 2025, aiming to diversify its product offerings [6] - InMode remains committed to maintaining its workforce and not cutting costs, believing this will position the company to lead when market conditions improve [5] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing macroeconomic uncertainty and soft consumer demand affecting the medical aesthetic market [4] - The company anticipates a potential reduction in operating margins by 4% to 5% due to market pressures and U.S. tariffs [13] Other Important Information - InMode completed a share repurchase program, buying back 6.95 million shares for $127 million, returning over $412 million to shareholders in the past year [7] - The company has a strong balance sheet with cash and equivalents totaling $512.9 million as of March 31, 2025 [12] Q&A Session Summary Question: Follow-up on product mix dynamics - Management indicated that the slowdown began in mid-2023 due to rising interest rates and decreased consumer confidence, impacting capital equipment purchases [19] Question: Guidance for Q2 and market recovery - Management expressed optimism for Q2 but noted that if results do not improve significantly, guidance may need to be lowered [30] Question: Impact of tariffs on gross margins - Management explained that current tariffs could impact gross margins by approximately 2% to 3% if they remain at 10% [56] Question: Updates on operating expenses - Management confirmed that they plan to maintain investments in sales and marketing despite macro challenges [63] Question: Pricing strategy in the current market - Management decided against raising prices due to the current market conditions, emphasizing the importance of maintaining competitiveness [70] Question: Performance in Europe compared to the U.S. - Management noted that Europe performed better in Q1 2025, attributed to management changes and pricing strategies [83]

Financial Data and Key Metrics Changes - InMode generated total revenue of $77.9 million in Q1 2025, a decrease of 3% compared to Q1 2024 [8] - GAAP gross margin was 78% in Q1 2025, down from 80% in Q1 2024 [8] - Non-GAAP diluted earnings per share were $0.31, compared to $0.32 in Q1 2024 [12] - The company ended the quarter with cash and cash equivalents of $512.9 million [12] Business Line Data and Key Metrics Changes - Minimally invasive platforms accounted for 87% of total revenues in Q1 2025 [9] - Sales and marketing expenses decreased slightly to $39.7 million in Q1 2025 from $39.8 million in Q1 2024 [11] Market Data and Key Metrics Changes - International sales accounted for $38 million or 49% of total sales, a 1% increase compared to Q1 2024 [9] - Europe was the largest revenue contributor outside the U.S., achieving record sales [10] Company Strategy and Development Direction - The company plans to unveil a new platform for the wellness market later this year, reflecting its strategy to diversify offerings [6] - InMode has committed to not reducing its workforce and aims to lead the industry during the market rebound [6] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing macroeconomic uncertainty and soft consumer demand affecting the medical aesthetic market [4] - The company remains optimistic about a recovery in consumer interest in minimally invasive procedures as macro conditions stabilize [5] - Management expects operating margins to decrease by 4% to 5% due to market pressures and U.S. tariffs [13] Other Important Information - InMode returned over $412 million to shareholders through share repurchases over the past twelve months, representing approximately 27% of total capital [7] - The company anticipates a potential impact of 2% to 3% on gross margins due to U.S. tariffs [14] Q&A Session Summary Question: Follow-up on product mix dynamics - Management indicated that the slowdown began in mid-2023 due to rising interest rates and decreased consumer confidence, impacting capital equipment purchases [20][21] Question: Guidance for Q2 and market trends - Management is optimistic about Q2 but will adjust guidance if results do not improve significantly compared to Q1 [30][31] Question: Impact of the macroeconomic environment on guidance - Management reiterated that guidance remains unchanged for now, pending Q2 results [39] Question: Updates on U.S. management structure - The company has not yet hired a new President for the U.S. and management is actively involved in operations [66] Question: Tariff impact and pricing strategy - Management decided not to raise prices due to market conditions, despite tariff impacts [70][71] Question: Performance in Europe - Europe performed better than the U.S. in Q1, attributed to management changes and pricing strategies [84]